Teva Pharmaceutical gets tentative FDA approval for drug in patent dispute
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) Wednesday said the Food and Drug Administration had granted tentative approval to the company's abbreviated new drug application to market a gastric-acid pump inhibitor.
The product is a generic form of TAP Pharmaceutical's drug Prevacid. Teva is currently involved in patent dispute litigation over the drug.
The count ruling over the case said it would issue a decision about the trial before June 7, when the mandatory 30-month stay of FDA approval associated with the litigation expires.Shares of Teva fell 1.9% to $45.03 on Wednesday.
Source : money.cnn.com
The product is a generic form of TAP Pharmaceutical's drug Prevacid. Teva is currently involved in patent dispute litigation over the drug.
The count ruling over the case said it would issue a decision about the trial before June 7, when the mandatory 30-month stay of FDA approval associated with the litigation expires.Shares of Teva fell 1.9% to $45.03 on Wednesday.
Source : money.cnn.com
Posts
Post a Comment